An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus
- PMID: 18382647
- PMCID: PMC2095096
- DOI: 10.1155/2006/152612
An Outbreak of Human Coronavirus OC43 Infection and Serological Cross-reactivity with SARS Coronavirus
Abstract
Background: In summer 2003, a respiratory outbreak was investigated in British Columbia, during which nucleic acid tests and serology unexpectedly indicated reactivity for severe acute respiratory syndrome coronavirus (SARS-CoV).
Methods: Cases at a care facility were epidemiologically characterized and sequentially investigated for conventional agents of respiratory infection, SARS-CoV and other human CoVs. Serological cross-reactivity between SARS-CoV and human CoV-OC43 (HCoV-OC43) was investigated by peptide spot assay.
Results: Ninety-five of 142 residents (67%) and 53 of 160 staff members (33%) experienced symptoms of respiratory infection. Symptomatic residents experienced cough (66%), fever (21%) and pneumonia (12%). Eight residents died, six with pneumonia. No staff members developed pneumonia. Findings on reverse transcriptase-polymerase chain reaction assays for SARS-CoV at a national reference laboratory were suspected to represent false positives, but this was confounded by concurrent identification of antibody to N protein on serology. Subsequent testing by reverse transcriptase-polymerase chain reaction confirmed HCoV-OC43 infection. Convalescent serology ruled out SARS. Notably, sera demonstrated cross-reactivity against nucleocapsid peptide sequences common to HCoV-OC43 and SARS-CoV.
Conclusions: These findings underscore the virulence of human CoV-OC43 in elderly populations and confirm that cross-reactivity to antibody against nucleocapsid proteins from these viruses must be considered when interpreting serological tests for SARS-CoV.
Keywords: Coronavirus; Human coronavirus OC43; Outbreak; Respiratory infection; SARS coronavirus; SARS-CoV; Severe acute respiratory syndrome.
Figures


Similar articles
-
Evaluation of human coronavirus OC43 and SARS-COV-2 in children with respiratory tract infection during the COVID-19 pandemic.J Med Virol. 2022 Apr;94(4):1450-1456. doi: 10.1002/jmv.27460. Epub 2021 Nov 24. J Med Virol. 2022. PMID: 34786736 Free PMC article.
-
Fully automated detection and differentiation of pandemic and endemic coronaviruses (NL63, 229E, HKU1, OC43 and SARS-CoV-2) on the hologic panther fusion.J Med Virol. 2021 Jul;93(7):4438-4445. doi: 10.1002/jmv.26749. J Med Virol. 2021. PMID: 33350484
-
Immunoreactivity characterisation of the three structural regions of the human coronavirus OC43 nucleocapsid protein by Western blot: implications for the diagnosis of coronavirus infection.J Virol Methods. 2013 Feb;187(2):413-20. doi: 10.1016/j.jviromet.2012.11.009. Epub 2012 Nov 19. J Virol Methods. 2013. PMID: 23174159 Free PMC article.
-
[Coronaviruses as the cause of respiratory infections].Internist (Berl). 2019 Nov;60(11):1136-1145. doi: 10.1007/s00108-019-00671-5. Internist (Berl). 2019. PMID: 31455974 Free PMC article. Review. German.
-
Human and novel coronavirus infections in children: a review.Paediatr Int Child Health. 2021 Feb;41(1):36-55. doi: 10.1080/20469047.2020.1781356. Epub 2020 Jun 25. Paediatr Int Child Health. 2021. PMID: 32584199 Review.
Cited by
-
What's new in critical illness and injury science? Intravenous immunoglobulin for COVID-19 with severe or critical illness.Int J Crit Illn Inj Sci. 2020 Oct-Dec;10(4):159-162. doi: 10.4103/IJCIIS.IJCIIS_192_20. Epub 2020 Dec 29. Int J Crit Illn Inj Sci. 2020. PMID: 33850822 Free PMC article. No abstract available.
-
Parkinson's Disease in the Era of a Novel Respiratory Virus Pandemic.Front Neurol. 2020 Sep 11;11:995. doi: 10.3389/fneur.2020.00995. eCollection 2020. Front Neurol. 2020. PMID: 33013657 Free PMC article. No abstract available.
-
A systematic review of antibody mediated immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody responses with severity of disease.medRxiv [Preprint]. 2020 Apr 17:2020.04.14.20065771. doi: 10.1101/2020.04.14.20065771. medRxiv. 2020. Update in: Nat Commun. 2020 Sep 17;11(1):4704. doi: 10.1038/s41467-020-18450-4. PMID: 32511434 Free PMC article. Updated. Preprint.
-
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.Sci Immunol. 2020 Jun 11;5(48):eabc8413. doi: 10.1126/sciimmunol.abc8413. Sci Immunol. 2020. PMID: 32527802 Free PMC article.
-
A six-year descriptive epidemiological study of human coronavirus infections in hospitalized patients in Hong Kong.Virol Sin. 2016 Feb;31(1):41-8. doi: 10.1007/s12250-016-3714-8. Epub 2016 Feb 23. Virol Sin. 2016. PMID: 26920709 Free PMC article.
References
-
- World Health Organization. Update 96 - Taiwan, China: SARS transmission interrupted in last outbreak area <www.who.int/csr/ don/2003_07_05/en> (Version current at November 6, 2006).
-
- Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003;348:1953-66. - PubMed
-
- Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003;348:1967-76. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous